Research Article
Bone Marrow Mesenchymal Stem Cells in Acute-on-Chronic Liver Failure Grades 2 and 3: A Phase I-II Randomized Clinical Trial
Table 2
Biochemical and clinical scores of patients at baseline.
| | Characteristics | All (n = 9) | MSC group (n = 4) | Placebo group (n = 5) |
| | Hb (g/dL) | 9.5 ± 1.8 | 10.0 ± 1.3 | 9.0 ± 2.1 | | WBC (mm3) | 9655.6 ± 599.3 | 7792.5 ± 5297.1 | 11146.0 ± 6668.9 | | PLT (×109/mm3) | 72.2 ± 58.1 | 53.5 ± 12.2 | 87.2 ± 77.5 | | TBili (mg/dL) | 11.5 ± 10.3 | 12.4 ± 11.5 | 10.9 ± 10.6 | | INR | 3.5 ± 1.5 | 3.9 ± 2.1 | 3.1 ± 0.8 | | sALB (g/dL) | 2.7 ± 0.7 | 3.0 ± 1.0 | 2.4 ± 0.3 | | Cr (mg/dL) | 2.8 ± 1.0 | 2.9 ± 0.8 | 2.7 ± 1.2 | | Na (mEq/L) | 138.1 ± 4.9 | 140.5 ± 5.2 | 136.2 ± 4.1 | | AST (U/L) | 102.1 ± 69.4 | 103 ± 54.7 | 101.4 ± 85.9 | | ALT (U/L) | 95.9 ± 137.5 | 75.2 ± 42.9 | 112.4 ± 188.9 | | ALP (U/L) | 114.9 ± 67.2 | 92.0 ± 54 | 133.2 ± 76.9 | | GGT (U/L) | 106.0 ± 109.2 | 62.0 ± 4.2 | 123.6 ± 128.6 | | CRP (mg/dL) | 54.0 ± 25.7 | 45.5 ± 23.6 | 60.8 ± 27.8 | | Child–Pugh | 12.7 ± 1.2 | 12.2 ± 1.7 | 13.0 ± 0.7 | | MELD | 38.4 ± 7.3 | 38.0 ± 11.3 | 38.8 ± 2.9 | | MELD-Na | 37.8 ± 6.7 | 39.0 ± 10.2 | 36.8 ± 2.9 | | ACLF grade | 2.3 ± 0.5 | 2.5 ± 0.6 | 2.2 ± 0.4 | | CLIF-C | 50.7 ± 10.9 | 51.2 ± 6.2 | 50.2 ± 14.4 |
|
|
value from Mann–Whitney U test. MSC, mesenchymal stem cells; Hb, hemoglobin; WBC, white blood cell; PLT, platelet; TBili, total bilirubin; INR, international normalized ratio; sALB, serum albumin; Cr, creatinine; Na, sodium; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; CRP, C-reactive protein; MELD, model for end-stage liver disease; ACLF, acute-on-chronic liver failure; CLIF-C, chronic liver failure consortium ( https://www.clifresearch.com/ToolsCalculators.aspx). |
